AIRAmed GmbH

AIRAmed GmbH: Revolutionizing Neurodegenerative Disease Diagnosis

Founded in 2019 and headquartered in Germany, AIRAmed GmbH is a health tech startup determined to make a difference in the medical field by leveraging AI software to optimize neuroradiological diagnostics and enable the early detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and multiple sclerosis.

Driven by the mission to improve medical care for the approximately 64.8 million people worldwide currently affected by dementia, AIRAmed has developed innovative software solutions based on neural networks. These solutions introduce objective measurability into radiological reporting, enabling standardized and objective findings based on exact measurement values.

As dementia ranks as the second most feared disease in society after cancer, the significance of quantitative software solutions for early detection cannot be overstated. The AIRAscore software solutions play a critical role in enabling the early detection of deviations, which might not be detectable through conventional visual examinations.

The ultimate goal is to empower attending physicians to identify certain clinical pictures much earlier, initiate appropriate therapies in time, and monitor individual therapy successes throughout the treatment process, all based on objective measurement parameters of the brain.

AIRAmed is driven by precision, innovation, and a passion for enhancing the latest scientific knowledge to benefit patients. The company is poised for significant growth and impact, offering a promising investment opportunity for venture capitalists seeking to drive innovation and positive change in the healthcare industry.